Servier said its experimental muscular dystrophy drug sevasemten failed to slow disease progression in Becker muscular dystrophy in the Phase 3 GRAND CANYON pivotal trial. The French company had bought the asset in June for $1.55 billion upfront, with up to about $1 billion more in potential milestones. The failure marks a major turn for both Servier and patients in the rare disease, who currently have no approved treatments. Servier said results were not aligned with findings from earlier studies and is conducting a comprehensive analysis of the GRAND CANYON dataset alongside prior clinical data. The move highlights the risk profile for large, late-stage takeout bets in rare neuromuscular indications when earlier signals do not translate in registrational trial settings.